Anti-obesity medications, the new frontiers in metabolic dysfunction-associated fatty liver disease: Efficacy, limitations, and future directions

The convergence of the global obesity and metabolic dysfunction-associated fatty liver disease (MAFLD) pandemics necessitates innovative therapeutic strategies. Anti-obesity medications, especially incretin-based treatments such as glucagon-like peptide-1 receptor agonists and multi-agonists (e.g. , tirzepatide, retatrutide), have shown a strong ability to reduce body weight and to significantly improve inflammation, hepatic steatosis, and MAFLD biomarkers. The mechanistic transition from satiet